p53 functional loss in a colon cancer cell line with two missense mutations (2181eu and 248trp) on separate alleles

Cancer Letters

Volumn 98, Issue 2, 1996, Pages 183-191

  Rand, A ^a   Glenn, K S ^a   Alvares, C P ^b   White, M B ^b   Thibodeau, S M ^a   Karnes Jr , W E ^a  

^a MAYO CLINIC   (United States)

^b Oncormed Inc   (United States)

Author keywords

Colon cancer cell line; Missense mutation; p53

Indexed keywords

BLEOMYCIN; MUTANT PROTEIN; PROTEIN P53; TRANSACTIVATOR PROTEIN;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE LOSS; HUMAN; HUMAN CELL; MISSENSE MUTATION; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; YEAST;

ALLELES; CELL DIVISION; COLONIC NEOPLASMS; DNA DAMAGE; DNA, NEOPLASM; GENES, P53; HETEROZYGOTE; HUMANS; LEUCINE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; TRYPTOPHAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

BACTERIA (MICROORGANISMS);

EID: 0030033046     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(95)04019-6     Document Type: Article

References (41)

1. Anonymous (1990) Current Protocols in Molecular Biology. Editors: F.A. Ausubel, R. Brent, R.E. Kingston, D.D. More, J.G. Seidman, J.A. Smith and K. Struhl. Wiley, New York.
2. Cariello, N.F., Cui, L., Beroud, C. and Soussi, T. (1994) Database and software for the analysis of mutations in the human p53 gene. Cancer Res., 54, 4454-4460.
3. Caron de Fromentel, C. and Soussi, T. (1992) TP53 tumor suppressor gene: a model for investigating human mutagenesis. [Review]. Genes Chromosomes Cancer, 4, 1-15.
4. Chen, J.J., Jackson, P.K., Kirschner, M.W. and Dutta, A. (1995) Separate domains of p21 involved in the inhibition of CDK kinase and PCNA. Nature, 374, 386-388.
5. Chin, K.V., Ueda, K., Pastan, I. and Gottesman, M.M. (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459-462.
6. Cho, Y.J., Gorina, S., Jeffrey, P.D. and Pavletich, N.P. (1994) Crystal structure of a p53 tumor suppressor DNA complex - understanding tumorigenic mutations. Science, 265, 346-355.
7. Clore, G.M., Omichinski, J.G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E. and Gronenborn, A.M. (1994) High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265, 386-391.
8. Deb, S.P., Munoz, R.M., Brown, D.R., Subler, M.A. and Deb, S. (1994) Wild-type human p53 activates the human epidermal growth factor receptor promoter [Review]. Oncogene, 9, 1341-1349.
9. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M., Finlay, C. and Levine, A.J. (1993) Gain of function mutations in p53. Nature Genet., 4, 42-46.
10. Dulic, V., Kaufmann, W.K., Wilson, S.J., Tlsty, T.D., Lees, E., Harper, J.W., Elledge, S.J. and Reed, S.I. (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-1023.
11. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
12. Ernest, S., Kawasaki, E.S. and Wang, A.M. (1989), Detection of gene expression. In: Technology: Principles and Applications for DNA Amplification, pp. 89-97. Editor: H.A. Erlich. Stockton Press, New York.
13. Forrester, K., Lupold, S.E., Ott, V.L., Chay, C.H., Band, V., Wang, X.W. and Harris, C.C. (1995) Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103-2111.
14. Frebourg, T., Sadelain, M., Ng, Y.S., Kassel, J. and Friend, S.H. (1994) Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res., 54, 878-881.
15. Hartwell, L. (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. [Review]. Cell, 71, 543-546.
16. Ishioka, C., Frebourg, T., Yan, Y.X., Vidal, M., Friend, S.H., Schmidt, S. and Iggo, R (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genet., 5, 124-129
17. Jenkins, R.B., Kimmel, D.W., Moertel, C.A., Schultz, C.G., Scheithauer, B.W., Kelly, P.J. and Dewald, G.W. (1989) A cytogenetic study of 53 human gliomas. Cancer Genet. Cytogenet., 39, 253-279.
18. Karnes, W.E.J., Walsh, J.H., Wu, S.V., Kim, R.S., Martin, M.G., Wong, H.C., Mendelsohn, J., Park, J. and Cuttitta, F. (1992) Autonomous proliferation of colon carcinoma cells that co-express transforming growth factor-alpha and its receptor: variable effects of receptor-blocking antibody. Gastroenterology, 102, 474-485.
19. Kastan, M.B., Zhan, Q., el Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B. and Fornace, Jr., A.J., (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587-597.
20. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227, 680-685.
21. Lane, D.P. (1992) Cancer. p53, guardian of the genome [news; comment] [see comments]. Nature, 358, 15-16.
22. Levine, A.J. (1993) The tumor suppressor genes. [Review]. Annu. Rev. Biochem., 62, 623-651.
23. Livingstone, L.R., White, A., Sprouse, I., Livanos, E., Jacks, T. and Tlsty, T.D. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935.
24. Milner, J. and Medcalf, E.A. (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65, 765-774.
25. Milner, J., Medcalf, E.A. and Cook, A.C. (1991) Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol., 11, 12-19.
26. Miyashita, T., Harigai, M., Hanada, M. and Reed, J.C. (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54, 3131-3135.
27. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
28. Nelson, W.G. and Kastan, M.B. (1994) DNA strand breaks - the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14, 1815-1823.
29. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C. and Vogelstein, B. (1989) Mutations in the human p53 gene occur in diverse human tumour types. Nature, 342, 705-708.
30. Park, J., Oie, H.K., Sugarbaker, P.H., Henslee, J.G., Chen, T., Johnson, B.E. and Gazdar, A.F. (1987) Characteristics of cell lines established from human colorectal carcinoma. Cancer Res., 47, 6710-6718.
31. Peacock, J.W. and Benchimol, S. (1994) Mutation of the endogenous p53 gene in cell transformed by HPV-16 E7 and EJ c-ras confers a growth advantage involving an autocrine mechanism. EMBO J., 13, 1084-1092.
32. Persons, D.L., Gibney, D.J., Katzmann, J.A., Lieber, M.M., Farrow, G.M. and Jenkins, R.B. (1993) Use of fluorescent in situ hybridization for deoxyribonuleic acid ploidy analysis of prostatic adenocarcinoma. J. Urol., 150, 120-125.
33. Ponchel, F., Puisieux, A., Tabone, E., Michot, J.P., Froschl, G., Morel, A.P., Frebourg, T., Fontaniere, B., Oberhammer, F. and Ozturk, M. (1994) Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta-1-mediated apoptosis. Cancer Res., 54, 2064-2068.
34. Rasheed, B.K.A., Mclendon, R.E., Herndon, J.E., Friedman, A.H., Bigner, D.D. and Bigner, S.H. (1994) Alterations of the tp53 gene in human gliomas. Cancer Res., 54, 1324-1330.
35. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J. and Howley, P.M. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-1136.
36. Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A. and Rotter, V. (1990) Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol., 10, 6565-6577.
37. Smith, M.L., Chen, I.T., Zhan, Q.M., Bae, I.S., Chen, C.Y., Gilmer, T.M., Kastan, M.B., O'Connor, P.M. and Fornace, A.J. (1994) Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science, 266, 1376-1380.
38. Tounekti, O., Pron, G., Belehradek, J. and Mir, L.M. (1993) Bleomycin, an apoptosis-mimetic drug that induces 2 types of cell death depending on the number of molecules internalized. Cancer Res., 53, 5462-5469.
39. Vogelstein, B. (1990) Cancer. A deadly inheritance. Nature, 348, 681-682.
40. Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C. and Wahl, G.M. (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
41. Zhang, W., Guo, X.Y., Hu, G.Y., Liu, W.B., Shay, J.W. and Deisseroth, A.B. (1994) A temperature-sensitive mutant of human p53. EMBO J., 13, 2535-2544.